home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505d.zip
/
M9550873.TXT
< prev
next >
Wrap
Text File
|
1995-03-25
|
2KB
|
33 lines
Document 0873
DOCN M9550873
TI Nucleoside reverse transcriptase inhibitors and resistance of human
immunodeficiency virus type 1.
DT 9505
AU Johnson VA; Department of Medicine, University of Alabama at Birmingham;
35294-0006.
SO J Infect Dis. 1995 Mar;171 Suppl 2:S140-9. Unique Identifier : AIDSLINE
MED/95164990
AB Drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1)
emerge during long-term treatment with nucleoside reverse transcriptase
inhibitors, such as zidovudine. The clinical significance of in vitro
drug resistance to zidovudine has been difficult to determine. However,
in a virologic analysis of baseline specimens from the AIDS Clinical
Trials Group (ACTG) 116B/117 study, high-level zidovudine resistance,
defined as an IC50 of > or = 1 microM at study entry, was significantly
associated with clinical disease progression. High-level zidovudine
resistance also was an independent predictor of death as an end point,
although this finding does not imply a direct causal effect. Duration
and cumulative dose of prior zidovudine therapy did not predict clinical
disease progression. More potent antiretroviral agents are needed that
can be used in combination to achieve more complete virus suppression
and to reduce the selection of drug-resistant HIV-1 mutants.
DE Clinical Trials Didanosine/THERAPEUTIC USE
Dideoxynucleosides/*THERAPEUTIC USE Drug Resistance Human HIV
Infections/*DRUG THERAPY HIV-1/*DRUG EFFECTS Support, Non-U.S. Gov't
Support, U.S. Gov't, Non-P.H.S. Support, U.S. Gov't, P.H.S.
Zidovudine/THERAPEUTIC USE JOURNAL ARTICLE REVIEW REVIEW, ACADEMIC
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).